Tobey J Betthauser1,2, Patrick J Lao3,2, Dhanabalan Murali3, Todd E Barnhart3, Shozo Furumoto4, Nobuyuki Okamura5, Charles K Stone6, Sterling C Johnson7,8, Bradley T Christian3,2. 1. Department of Medical Physics, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin tbetthauser@wisc.edu. 2. Waisman Laboratory for Brain Imaging and Behavior, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin. 3. Department of Medical Physics, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin. 4. Division of Radiopharmaceutical Neuroimaging, Tohoku University, Sendai, Japan. 5. Division of Pharmacology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan. 6. Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin. 7. Geriatric Research Education and Clinical Center, William S. Middleton Veterans Hospital, Madison, Wisconsin; and. 8. Wisconsin Alzheimer's Institute, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin.
Abstract
This study compared the in vivo imaging characteristics of tau PET ligands 18F-THK-5351 and 18F-THK-5317 in the context of Alzheimer disease (AD). Additionally, reference tissue distribution volume ratio (DVR) estimation methods and SUV ratio (SUVR) timing windows were evaluated to determine the optimal strategy for specific binding quantification. Methods: Twenty-eight subjects (mean age ± SD, 71 ± 7 y) underwent either dynamic 90-min 18F-THK-5317 or 18F-THK-5351 PET scans. Bland-Altman plots were used to compare the simplified reference tissue method, multilinear reference tissue method (MRTM2), and Logan reference tissue DVR estimates and to assess temporal stability of SUVR windows using cerebellar gray matter as a reference region. In vivo kinetics and DVR estimates were directly compared for 10 subjects who underwent both 18F-THK-5317 and 18F-THK-5351 PET scans. Results: THK-5351 exhibited faster cerebellar gray matter clearance, faster cortical white matter clearance, and higher DVR estimates in AD tau-associated regions of interest than THK-5317. The MRTM2 method produced the most reliable DVR estimates for both tracers, particularly when scan duration was shortened to 60 min. SUVR stability was observed 50-70 min after injection for both tracers. Parametric images revealed differences between MRTM2, Logan, and SUVR binding in white matter regions for THK-5317. Conclusion: THK-5317 and THK-5351 show promise for in vivo detection of AD tau. THK-5351 has more favorable pharmacokinetics and imaging characteristics than THK-5317.
This study compared the in vivo imaging characteristics of tau PET ligands 18F-THK-5351 and 18F-THK-5317 in the context of Alzheimer disease (AD). Additionally, reference tissue distribution volume ratio (DVR) estimation methods and SUV ratio (SUVR) timing windows were evaluated to determine the optimal strategy for specific binding quantification. Methods: Twenty-eight subjects (mean age ± SD, 71 ± 7 y) underwent either dynamic 90-min 18F-THK-5317 or 18F-THK-5351 PET scans. Bland-Altman plots were used to compare the simplified reference tissue method, multilinear reference tissue method (MRTM2), and Logan reference tissue DVR estimates and to assess temporal stability of SUVR windows using cerebellar gray matter as a reference region. In vivo kinetics and DVR estimates were directly compared for 10 subjects who underwent both 18F-THK-5317 and 18F-THK-5351 PET scans. Results:THK-5351 exhibited faster cerebellar gray matter clearance, faster cortical white matter clearance, and higher DVR estimates in ADtau-associated regions of interest than THK-5317. The MRTM2 method produced the most reliable DVR estimates for both tracers, particularly when scan duration was shortened to 60 min. SUVR stability was observed 50-70 min after injection for both tracers. Parametric images revealed differences between MRTM2, Logan, and SUVR binding in white matter regions for THK-5317. Conclusion:THK-5317 and THK-5351 show promise for in vivo detection of ADtau. THK-5351 has more favorable pharmacokinetics and imaging characteristics than THK-5317.
Authors: John M Floberg; Charles A Mistretta; Jamey P Weichert; Lance T Hall; James E Holden; Bradley T Christian Journal: Med Phys Date: 2012-06 Impact factor: 4.071
Authors: Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson Journal: J Cereb Blood Flow Metab Date: 2007-05-09 Impact factor: 6.200
Authors: Eric D Hostetler; Abbas M Walji; Zhizhen Zeng; Patricia Miller; Idriss Bennacef; Cristian Salinas; Brett Connolly; Liza Gantert; Hyking Haley; Marie Holahan; Mona Purcell; Kerry Riffel; Talakad G Lohith; Paul Coleman; Aileen Soriano; Aimie Ogawa; Serena Xu; Xiaoping Zhang; Elizabeth Joshi; Joseph Della Rocca; David Hesk; David J Schenk; Jeffrey L Evelhoch Journal: J Nucl Med Date: 2016-05-26 Impact factor: 10.057
Authors: Keith A Johnson; Aaron Schultz; Rebecca A Betensky; J Alex Becker; Jorge Sepulcre; Dorene Rentz; Elizabeth Mormino; Jasmeer Chhatwal; Rebecca Amariglio; Kate Papp; Gad Marshall; Mark Albers; Samantha Mauro; Lesley Pepin; Jonathan Alverio; Kelly Judge; Marlie Philiossaint; Timothy Shoup; Daniel Yokell; Bradford Dickerson; Teresa Gomez-Isla; Bradley Hyman; Neil Vasdev; Reisa Sperling Journal: Ann Neurol Date: 2015-12-15 Impact factor: 10.422
Authors: Konstantinos Chiotis; Laure Saint-Aubert; Irina Savitcheva; Vesna Jelic; Pia Andersen; My Jonasson; Jonas Eriksson; Mark Lubberink; Ove Almkvist; Anders Wall; Gunnar Antoni; Agneta Nordberg Journal: Eur J Nucl Med Mol Imaging Date: 2016-03-21 Impact factor: 9.236
Authors: Tobey J Betthauser; Paul A Ellison; Dhanabalan Murali; Patrick J Lao; Todd E Barnhart; Shozo Furumoto; Nobuyuki Okamura; Sterling C Johnson; Jonathan W Engle; Robert J Nickles; Bradley T Christian Journal: Appl Radiat Isot Date: 2017-10-04 Impact factor: 1.513
Authors: Matthias Brendel; Sonja Schönecker; Günter Höglinger; Simon Lindner; Joachim Havla; Janusch Blautzik; Julia Sauerbeck; Guido Rohrer; Christian Zach; Franziska Vettermann; Anthony E Lang; Lawrence Golbe; Georg Nübling; Peter Bartenstein; Katsutoshi Furukawa; Aiko Ishiki; Kai Bötzel; Adrian Danek; Nobuyuki Okamura; Johannes Levin; Axel Rominger Journal: Front Aging Neurosci Date: 2018-01-17 Impact factor: 5.750